<DOC>
	<DOCNO>NCT00791349</DOCNO>
	<brief_summary>The purpose study ass cardiovascular safety paliperidone patient schizophrenia schizoaffective disorder , particular attention length QT/QTc interval , measure review electrocardiogram ( ECG ) parameter , QRS PR interval , explore relationship pharmacokinetics paliperidone ECG parameter interest , explore safety tolerability paliperidone</brief_summary>
	<brief_title>A Study QT QTc Intervals Patients Administered Immediate Release Paliperidone</brief_title>
	<detailed_description>This multicenter , placebo- positive-controlled , randomize study consist 3 period : screening period 14 day ( include 5-day washout period ) , double-blind period 10 day ( include treatment phase [ Days 1 8 ] posttreatment phase [ Days 9 10 ] ) , end-of-study evaluation . Eligible patient randomly assign treatment either paliperidone moxifloxacin . Patients randomly assign receive paliperidone receive placebo Day 1 , paliperidone 4 mg Day 2 , paliperidone 6 mg Day 3 , paliperidone 8 mg Days 4 8 . Patients assign receive moxifloxacin receive placebo Days 1 7 moxifloxacin 400 mg Day 8 . The moxifloxacin treatment group provide concurrent active control confirm study adequate detect drug effect ( i.e. , assay sensitivity ) QTc interval . Baseline ECGs record last day washout period ( Day 1 ) . Serial time match 12 lead ECG triplicate reading record Days 1 , 2 , 3 , 4 , 5 ( predose ) , 8 , 9 , 10 . This study conduct thoroughly assess potential QT/QTc interval change follow administration paliperidone . The result safety study , along ECG result paliperidone clinical study , use evaluation cardiovascular safety paliperidone . Paliperidone IR orally daily : 4 mg Day 2 , 6 mg Day 3 , 8 mg Days 4 8 ; Active control : single oral dose moxifloxacin 400 mg Day 8</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients must diagnosis schizophrenia schizoaffective disorder define DSMIV criterion , exacerbation psychosis least 3 month prior screen Patients must normal 12lead ECG screen Day 1 , include : Normal sinus rhythm ( heart rate 50 100 beat per minute ) QTcB interval &lt; = 430 msec men , &lt; = 450 msec woman QRS interval &lt; 110 msec , PR interval &lt; 200 msec Patients must weigh &gt; = 50 kg ( &gt; = 110 lb ) , body mass index &gt; = 18 &lt; = 35 kg/m2 Female patient must postmenopausal ( least 1 year ) , surgically sterile , practice effective nonhormonal method birth control ( e.g. , intrauterine device , doublebarrier method , male partner sterilization , abstinence ) entry throughout study must negative serum beta human chorionic gonadotropin pregnancy test screening must negative urine pregnancy test within 24 hour Day 1 randomization period . Patient meet DSMIV criterion psychoactive substance dependence 3 month prior screen Patient risk suicidal violent behavior , judge investigator : Patient clinically significant abnormality ECG screen Day 1 study Patient heart rhythm disturbance know suggested history demonstrate ECG screen Patient blood pressure outside normal range ( supine systolic blood pressure &lt; 90 &gt; 140 mmHg and/or diastolic blood pressure &lt; 60 &gt; 90 mmHg ) Patient unusual Twave morphology majority lead ECG ( bifid T wave , low T wave ) prominent U wave screen : Patient history additional risk factor torsade de pointes , heart failure , hypokalemia , family history know long QT interval syndrome , sudden unexplained death young age ( &lt; = 40 year ) firstdegree relative ( i.e. , biological parent , sibling , offspring ) Patient relevant history significant and/or unstable cardiovascular , respiratory ( include bronchial asthma ) , neurologic ( include seizure significant cerebrovascular disease ) , renal , hepatic , endocrine , immunologic , ophthalmologic , hematological , systemic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Antipsychotic drug</keyword>
	<keyword>Cardiovascular</keyword>
	<keyword>Immediate release ( IR ) Paliperidone</keyword>
</DOC>